Influenza, commonly known as flu, is an infectious disease caused by influenza virus. Its symptoms can be mild to severe including runny nose, high fever, muscle and joints pain, headache, coughing, fatigue, and sore throat. There are two types of influenza namely pandemic and seasonal. Furthermore, seasonal influen.
Close
(Photo : Rapid Rona)
You might be wondering how to get tested for COVID-19 from the safety of your own home, knowing your test is as accurate as possible? Getting tested for the rapidly spreading ‘Rona’ is at the top of everyone’s to-do list right now. For people who understand the risk, to themselves or others, of leaving their homes, better solutions for testing are available.
Based in Chicago, RapidRona is a team of multi-disciplined experts passionate about creating a platform that connects the patient-consumer to smarter and safer diagnostic testing. Their new system for getting a COVID-19 rt-PCR test provides a unique process that facilitates a completely at-home test with a guaranteed 48-hour turnaround time. This article will discuss RapidRona s Self-Collection Kit, as well as their process for testing for COVID-19.
Share this article
SAN CARLOS, Calif., Feb. 3, 2021 /PRNewswire/
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cfDNA testing, presented key results from its SMART study at the SMFM 41st Annual Pregnancy Meeting.
1-3 The SMART study is the largest prospective, multi-site study ever performed in NIPT, and the only to collect genetic confirmation of outcomes on the vast majority of subjects. The study rigorously tested the performance of the current version of Panorama, confirming its market-leading performance in a real-world setting and extending Panorama s position as the most thoroughly studied NIPT on the market. The study also includes the validation of a new deep-learning, artificial intelligence-based algorithm for Panorama called Panorama AI, which utilizes information from over 2 million cfDNA tests performed by Natera.
To embed, copy and paste the code into your website or blog:
Clinical laboratories across the country have ramped up their diagnostic testing capabilities to meet the critical need for COVID-19 testing, which is essential to mitigating the spread of the virus. Many labs are responding to this unprecedented demand by testing specimens from different states and entering into arrangements with employers and other third parties to collect specimens. Despite provisions in recent federal laws and waivers[1] designed to make COVID-19 testing available and accessible on a widespread basis, labs must maintain compliance with federal and state laws.
CLIA: the Federal Floor
Credit: Copyright: George Mason University 2021
Mason scientists employ a rapid-result, saliva-based test that significantly expands testing capacity, and an antibody test that can track vaccine response.
George Mason University announces it is introducing a rapid-result, saliva-based COVID-19 test that will greatly expand testing capabilities on its campuses this spring. The effort, led by Mason s faculty, is part of a comprehensive program to better track and control the virus on campus.
Mason scientists, who are pushing the boundaries of technologies that are keeping Mason s campuses safe, are also developing an antibody test that can track a body s response to the virus and vaccine. See more in this video.